Short radiation, chemo, and immunotherapy before pancreas cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a short course of radiation combined with chemo and the immunotherapy drug camrelizumab before surgery for pancreatic cancer. It aims to shrink tumor to make removal easier and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are well enough to carry out daily activities (ECOG score 0-1).
- Your tumor is in the pancreas and is a common type called pancreatic ductal adenocarcinoma or acinar cell carcinoma.
- The cancer has not spread to other parts of your body.
- Your tumor is considered locally advanced or borderline resectable (meaning it is close to major blood vessels but may be removable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (liposomal irinotecan, 5-fluorouracil, oxaliplatin, and adebrelimab) given with radiation therapy before surgery for pancreatic cancer that can be surgically removed or is borderline removable. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) with chemotherapy before surgery for pancreatic cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for patients whose cancer can be surgically removed.
This trial tests a combination of chemotherapy drugs given before and after surgery for pancreatic cancer that is considered high-risk but removable. The goal is to see if this approach can improve outcomes for patients with this type of cancer.
This trial tests a combination of standard chemotherapy, MRI-guided radiation, and surgery for people with locally advanced pancreatic cancer that might be removable. The goal is to see if this approach can make more tumors resectable.
This trial compares adding radiation to chemotherapy versus chemotherapy alone after surgery for pancreatic cancer. It is for people whose cancer had certain high-risk features found during surgery, and who have not yet started additional treatment.
This trial tests whether giving radiation therapy before a combination of two chemotherapy drugs (NALIRIFOX) is better than chemotherapy alone for people with pancreatic cancer that is on the edge of being removable. The goal is to see if adding radiation helps shrink the tumor enough to make surgery possible and improve outcomes.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.